Moderna Sees Unusually High Options Volume (NASDAQ:MRNA)

Moderna, Inc. (NASDAQ:MRNA) saw unusually large options trading activity on Friday. Traders purchased 112,509 call options on the company. This represents an increase of approximately 32% compared to the average daily volume of 85,335 call options.

Insider Activity at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director owned 3,924 shares in the company, valued at $115,679.52. The trade was a 85.87% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Stephen Hoge sold 160,009 shares of the business’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $48.84, for a total value of $7,814,839.56. Following the completion of the sale, the president owned 1,457,427 shares of the company’s stock, valued at $71,180,734.68. This trade represents a 9.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 184,366 shares of company stock valued at $8,531,936 over the last 90 days. Company insiders own 10.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in Moderna during the 1st quarter worth approximately $415,000. NewEdge Advisors LLC grew its stake in shares of Moderna by 732.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,575 shares of the company’s stock worth $328,000 after acquiring an additional 10,185 shares in the last quarter. United Services Automobile Association bought a new position in shares of Moderna during the 1st quarter worth approximately $230,000. Focus Partners Wealth boosted its stake in shares of Moderna by 58.7% in the 1st quarter. Focus Partners Wealth now owns 23,547 shares of the company’s stock worth $668,000 after buying an additional 8,706 shares during the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Moderna by 137.7% in the second quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock valued at $36,000 after acquiring an additional 752 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Stock Performance

Shares of Moderna stock opened at $52.52 on Friday. The business has a 50-day moving average price of $43.13 and a two-hundred day moving average price of $32.23. Moderna has a 1-year low of $22.28 and a 1-year high of $59.55. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07. The company has a market cap of $20.74 billion, a P/E ratio of -7.22 and a beta of 1.29.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping the consensus estimate of ($2.79) by $0.68. The company had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. Moderna had a negative net margin of 145.16% and a negative return on equity of 30.15%. The company’s quarterly revenue was down 33.2% on a year-over-year basis. During the same quarter last year, the firm posted ($2.91) EPS. As a group, analysts anticipate that Moderna will post -9.61 EPS for the current year.

Moderna News Roundup

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Settlement clears legal overhang: Moderna reached deals to resolve long‑running LNP patent litigation, which investors interpret as removing a major uncertainty that had been capping the stock. The market initially reacted positively to news the dispute is resolved. Moderna to pay up to $2.25B to end mRNA vaccine patent fight Moderna fronts $950M to settle yearslong COVID patent litigation
• Positive Sentiment: Bullish options flow: Unusually heavy call buying (112,509 calls, ~32% above typical volume) signals short‑term bullish positioning by traders and could support intraday upside if flows continue. (No external link provided)
• Positive Sentiment: Retail interest and momentum: Retail chatter and short‑term momentum have helped lift the stock recently (double‑digit weekly moves and large YTD gains cited by coverage), which can amplify volatility around news. Reddit Traders Are Cheering Moderna While Bears Watch the Cash Burn
• Neutral Sentiment: Analyst and narrative pieces: Several outlets are revisiting Moderna’s investment case (pipeline potential, oncology vaccine upside) and whether today’s price is a buying opportunity — useful context but not immediate catalysts. Moderna Stock (MRNA): Is It a Buy Now?
• Neutral Sentiment: Market bounce context: Coverage grouping Moderna with other volatile names notes technical bounces and differing Wall Street views — helpful for traders but mixed for longer‑term investors. These 3 Stocks Just Bounced From Lows — What Wall Street Thinks Comes Next
• Negative Sentiment: Regulatory uncertainty: Reports highlighting recent FDA reversals and tougher scrutiny on new drug applications have increased investor concern that future approvals (e.g., respiratory or flu programs) could face delays or setbacks. That regulatory risk is pressuring the stock today. FDA reversals leave investors worrying about the fates of other experimental drugs
• Negative Sentiment: Cash/cost impact of the settlement: While the settlement removes legal overhang, it carries a material cash burden (Moderna may pay up to ~$2.25B and is fronting $950M), which renews concerns about cash burn and near‑term finances—an important negative for fundamental investors. Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

Analysts Set New Price Targets

Several brokerages recently issued reports on MRNA. Royal Bank Of Canada boosted their price target on Moderna from $25.00 to $30.00 and gave the company a “sector perform” rating in a research note on Tuesday, February 17th. Berenberg Bank set a $28.00 target price on shares of Moderna in a research report on Monday, November 17th. BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, January 29th. Finally, Evercore set a $35.00 price objective on shares of Moderna in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, Moderna presently has a consensus rating of “Reduce” and an average target price of $32.33.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.